Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Actinium-225 shows clinical activity in metastatic castration-resistant prostate cancer
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
Most combinations of cancer drugs have additive, but not synergistic efficacy
A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials
Lenvatinib plus pembrolizumab does not improve outcomes in NSCLC
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
Blocking GDF-15 may be promising to overcome resistance to immunotherapy
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy